San Francisco startup Framework Therapeutics is additionally working on an oral, after-day-to-day GLP-1 drug referred to as GSBR-1290—the drug surpassed Wall Street’s expectations in June when a mid-phase study showed normal weight loss of close to six% and it options to start A different mid-phase trial towards the top of the calendar year—t